All In Biotech

Drug Trial Radar · NCT00876161

DAS181 Single Dose Escalation Study in Healthy Adults

Phase 1 Clinical Study With DAS181: Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation Study in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Aug 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

May 18, 2009

Primary completion

Dec 2009

Study completion May 23, 2010

Sponsor

Lead sponsor
Ansun Biopharma, Inc.Industry
Sponsor type
Industry
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Apr 6, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, and systemic exposure of an experimental influenza (flu) treatment medication called DAS181. DAS181 is a dry powder that is administered via oral inhalation using a special device. Study participants will include healthy non-smoking males and females, ages 18-65. They will be given either DAS181 or placebo. Participants will remain in the clinic overnight to be watched for health changes for 24 hours after receiving the medication. Study procedures include: physical exams, chest x-rays, ECGs, lung function tests, collection of blood and urine samples, and throat swabs. Follow-up visits will occur on study days 2, 7, 14 and 30.

Conditions

  • Healthy

Interventions

  • DAS181Drug

    DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.

  • LactoseDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety, tolerability and pharmacokinetics of DAS181 dry powder inhalant single-dose treatment in healthy adults.Time frame: September 2009

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quintiles Phase One Services

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.